Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability

por Ericsson, Hans, Nelander, Karin, Heijer, Maria, Kjaer, Magnus, Lindstedt, Eva‐Lotte, Albayaty, Muna, Forte, Pablo, Lagerström‐Fermér, Maria, Skrtic, Stanko
Publicado 2019

4-Aminobutyrate Aminotransferase (ABAT): Genetic and Pharmacological Evidence for an Involvement in Gastro Esophageal Reflux Disease

por Jirholt, Johan, Åsling, Bengt, Hammond, Paul, Davidson, Geoffrey, Knutsson, Mikael, Walentinsson, Anna, Jensen, Jörgen M., Lehmann, Anders, Agreus, Lars, Lagerström-Fermer, Maria
Publicado 2011

Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial

por Anttila, Vesa, Saraste, Antti, Knuuti, Juhani, Jaakkola, Pekka, Hedman, Marja, Svedlund, Sara, Lagerström-Fermér, Maria, Kjaer, Magnus, Jeppsson, Anders, Gan, Li-Ming
Publicado 2020

Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy voluntee...

por Gan, Li‐Ming, Lagerström‐Fermér, Maria, Ericsson, Hans, Nelander, Karin, Lindstedt, Eva‐Lotte, Michaëlsson, Erik, Kjaer, Magnus, Heijer, Maria, Whatling, Carl, Fuhr, Rainard
Publicado 2019

Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction

por Nelander, Karin, Lagerstrom‐Fermer, Maria, Amilon, Carl, Michaëlsson, Erik, Heijer, Maria, Kjaer, Magnus, Russell, Muir, Han, David, Lindstedt, Eva‐Lotte, Whatling, Carl, Gan, Li‐Ming, Ericsson, Hans
Publicado 2021

Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction

por Erhardsson, Mikael, Ljung Faxén, Ulrika, Venkateshvaran, Ashwin, Svedlund, Sara, Saraste, Antti, Lagerström Fermer, Maria, Gan, Li‐Ming, Shah, Sanjiv J., Tromp, Jasper, SP Lam, Carolyn, Lund, Lars H., Hage, Camilla
Publicado 2023

Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction

por Prescott, Eva, Pernow, John, Saraste, Antti, Åkerblom, Axel, Angerås, Oskar, Erlinge, David, Grove, Erik L., Hedman, Marja, Jensen, Lisette O., Svedlund, Sara, Kjaer, Magnus, Lagerström-Fermér, Maria, Gan, Li-Ming
Publicado 2020

PROspective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: cross-sectional evaluation of coron...

por Haraldsson, Inger, Gan, Li-Ming, Svedlund, Sara, Torngren, Kristina, Westergren, Helena U, Redfors, Björn, Lagerström-Fermér, Maria, Angerås, Oskar, Råmunddal, Truls, Petursson, Petur, Odenstedt, Jacob, Albertsson, Per, Erlinge, David, Omerovic, Elmir
Publicado 2019

Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5‐Lipoxygenase Activating Protein Inhibitor

por Ericsson, Hans, Nelander, Karin, Lagerstrom‐Fermer, Maria, Balendran, Clare, Bhat, Maria, Chialda, Ligia, Gan, Li‐Ming, Heijer, Maria, Kjaer, Magnus, Lambert, John, Lindstedt, Eva‐Lotte, Forsberg, Gun‐Britt, Whatling, Carl, Skrtic, Stanko
Publicado 2018

Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction

por Chandramouli, Chanchal, Ting, Tay W., Tromp, Jasper, Agarwal, Anubha, Svedlund, Sara, Saraste, Antti, Hage, Camilla, Tan, Ru‐San, Beussink‐Nelson, Lauren, Lagerström Fermer, Maria, Gan, Li‐Ming, Lund, Lars, Shah, Sanjiv J., Lam, Carolyn S.P.
Publicado 2022

Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes

por Gan, Li-Ming, Lagerström-Fermér, Maria, Carlsson, Leif G., Arfvidsson, Cecilia, Egnell, Ann-Charlotte, Rudvik, Anna, Kjaer, Magnus, Collén, Anna, Thompson, James D., Joyal, John, Chialda, Ligia, Koernicke, Thomas, Fuhr, Rainard, Chien, Kenneth R., Fritsche-Danielson, Regina
Publicado 2019